A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results-Reference-Cited by-同舟云学术

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Published:2018-10 Issue: Volume:29 Page:viii372
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cohen E.E.W.,Harrington K.J.,Hong D.S.,Mesia R.,Brana I.,Perez Segura P.,Wise-Draper T.,Scott M.L.,Mitchell P.D.,Mugundu G.M.,McCoon P.,Cook C.E.,Mehta M.,Keilholz U.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy287/26140090/mdy287.pdf

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial;Cancer Discovery;2023-09-14

2. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study;BMJ Open;2022-10

3. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma;International Journal of Molecular Sciences;2022-07-17

4. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy;Pharmacology & Therapeutics;2022-07

5. Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers;Frontiers in Oncology;2022-03-17